In this video, health-care analyst David Williamson takes a closer look at Abbott Labs, which has seen its share of headlines this week. There was a big hepatitis C win, a high-profile drug failure, and a potential boost for its blockbuster. Amidst all this news, Wall Street has come out with a new recommendation on the stock. Watch and find out how this affects investors, and what may be the smartest way to play Abbott's spinoff.